×

AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2015

WALTHAM, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2015 before the U.S. financial markets open on Tuesday, May 5, 2015. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will discuss the company's financial results, business update, and growth prospects.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on May 5, 2015 through midnight on May 12, 2015. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 33122806.

The call will be webcast with slides and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on May 5, 2015 through midnight June 4, 2015.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies. For additional company information, please visit www.amagpharma.com.

CONTACT: AMAG Pharmaceuticals, Inc. Contact: Linda Lennox Vice President, Investor Relations & Corporate Communications 617-498-2846

Source:AMAG Pharmaceuticals, Inc.